Arpa, C.

Balaskas, K.

Chopra, R.

Faes, L.

Ferraz, D.

Fu, D. J.

Guan, Z.

Keane, P.

Khalid, H.

Montesano, G.

Moraes, G.

Soliman, N.

Wagner, S.

City Research Online

              City, University of London Institutional RepositoryCitation: Soliman, N., Arpa, C., Khalid, H., Fu, D. J., Montesano, G., Chopra, R., Faes, L., Moraes, G., Wagner, S., Ferraz, D., et al (2020). Ten-year visual outcomes in patients with treated neovascular age related macular degeneration receiving anti-VEGF therapy. Investigative Ophthalmology & Visual Science (IOVS), 61(7), ISSN 0146-0404 This is the published version of the paper. This version of the publication may differ from the final published version. Permanent repository link:  https://openaccess.city.ac.uk/id/eprint/27400/Link to published version: Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. City Research OnlineCity Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk1/4Ten-year visual outcomes in patients with treatedneovascular age related macular degenerationreceiving anti-VEGF therapy | IOVSiovs.arvojournals.org/article.aspxARVO Annual Meeting Abstract  |   June 2020Ten-year visual outcomes in patients with treated neovascular age related maculardegeneration receiving anti-VEGF therapyInvestigative Ophthalmology & Visual Science June 2020, Vol.61, 4231. doi:AbstractPurpose : Intravitreal injections of anti-vascular endothelial growth factor (VEGF) havebeen proven to be the most effective treatment for nAMD, although there is a lack ofsupported data from randomized controlled trials (RCTs) on outcomes after 7 years. Thepurpose of this report is to characterise visual outcome in neovascular AMD (nAMD)patients over 10 years following initiation of anti-VEGF.Methods : A retrospective cohort review of medical records was performed to collectpatients who had commenced intravitreal therapy for nAMD at Moorfields Eye Hospital(MEH) before January 1, 2009. The primary outcome was the visual function at 10 yearswhich was evaluated by estimating the mean visual acuity and the mean change in visionat 10 years. The proportion of eyes with good (≥70 letters) and poor final vision (≤35letters) at 10 years was also calculated, together with the time to BCVA ≤35 letters (6/60)and BCVA ≥70 letters (6/12).Results : Of the 103 patients who received intravitreal injections for nAMD beforeJanuary 2009, 56 patients (54.4%) were followed-up for the whole ten-year duration. Themean total number of injections per eye during the follow-up was 37.0 ± 24.2. Of those,29 (51.8%) were still on treatment at 10 years. Mean BCVA score at 10 years was 42.9 ±27.0 ETDRS letters and the mean BCVA change from baseline to the 10-year visit wasrepresented by a drop of 12.4 letters. The proportion of eyes with BCVA ≥70 and BCVA≤35 letters at 10 years were 21.3% and 41.1%, respectively. In addition, the median time toreach BCVA ≤35 was 37.8 months from baseline, while median time to reach BCVA ≥70letters was at 8.3 months (Figure 1 and 2). Time to BCVA ≤35 letters was negativelyassociated with baseline BCVA (HR 0.91; 95% CI 0.89-0.94) and positively associatedwith age (HR 1.08; 95% CI 1.04-1.12), while time to BCVA ≥70 letters was only positivelyassociated with baseline BCVA (HR 1.13; 95% CI 1.10-1.17). Interestingly, no significantassociation to number of injections was detected in either time to BCVA ≤35 letters (HR1.02; 95% CI 0.99-1.05) or to BCVA ≥70 letters (HR 0.99; 95% CI 0.93-1.06).Conclusions : This report offers both the clinician and the patient a plausible estimationof what to expect in the long term, how to balance the costs with the benefits, and how toprovide more corroborated information based on real-life experience.2/4This is a 2020 ARVO Annual Meeting abstract.3/4This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.4/4AdvertisementCopyright © 2015 Association for Research in Vision and Ophthalmology.  

Ten-year visual outcomes in patients with treated neovascular age related macular degeneration receiving anti-VEGF therapy

https://openaccess.city.ac.uk/id/eprint/27400/1/iovs.arvojournals.org-Ten-year%20visual%20outcomes%20in%20patients%20with%20treated%20neovascular%20age%20related%20macular%20degeneration%20receiv.pdf

Ten-year visual outcomes in patients with treated neovascular age related macular degeneration receiving anti-VEGF therapy

Abstract

Similar works

Full text

Available Versions

City Research Online